Sign up
Pharma Capital

Onzima's investee company N4 Pharma working on better drug than Viagra

Nigel Theobald, CEO of N4 Pharma, one of the portfolio companies of investment firm Onzima Ventures (LON:ONZ) talks to Proactive Investors about the company's business model, focused on the reformulation of drugs with an unmet commercial or medical  need.

Theobald says N4's proprietary platform delivery system focused on the reformulation of Sildenafil will help improve existing erectile dysfunction treatments such as Viagra and Cialis.

The company has recently filed 45 patents for this reformulation.

 

View full N4P profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.